Glenmark Pharmaceuticals Inc., USA has announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL), available in a single-dose vial format.
The launch adds another product to Glenmark’s growing institutional portfolio in the United States and reflects the company’s ongoing efforts to provide healthcare providers with access to affordable and reliable treatment options.
According to the company, Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), developed by Provepharm SAS under NDA 204630.
The approval allows Glenmark to offer a comparable alternative in the U.S. market while meeting regulatory standards established by the U.S. Food and Drug Administration (FDA).
The product is approved only for the indications listed in Glenmark’s approved prescribing information.
The launch comes as healthcare institutions continue to seek cost-effective treatment options without compromising on quality and regulatory compliance.
By introducing Methylene Blue Injection USP, Glenmark aims to strengthen its presence in the hospital and institutional healthcare segment while supporting patient access to essential medicines.
Commenting on the announcement, Marc Kikuchi, President and Business Head, North America, said the launch reflects Glenmark’s continued commitment to expanding access to high-quality and affordable medicines.
He noted that the addition of Methylene Blue Injection USP further strengthens the company’s institutional product portfolio and reinforces its focus on delivering dependable treatment options to healthcare providers and patients across the United States.
Strengthening Glenmark’s Presence in the U.S. Market
The launch of Methylene Blue Injection USP marks another step in Glenmark’s strategy to broaden its U.S. product offering. The company continues to focus on introducing generic medicines that help healthcare institutions manage treatment costs while ensuring product quality and availability.
With this addition, Glenmark further expands its range of injectable products designed to serve hospitals, clinics, and healthcare systems throughout the country.